Document Type

Article

Publication Date

12-31-2020

Comments

This is the final published version of the article from Cancers, 2020 Dec 31;13(1):103.

The full text of the article can also be found at the journal's website: https://doi.org/10.3390/cancers13010103

Copyright. The Authors.

Abstract

Immune checkpoint inhibitors (ICIs) are increasingly used for advanced lung cancer, butfew studies have reported on patient-reported outcomes (PROs) outside the context of a clinicaltrial. The goal of the current study was to assess PROs in participants of a lung cancer registry whohad been treated with an ICI. Patients participating in the GO2Foundation’s Lung Cancer Registrywho reported receiving atezolizumab, durvalumab, nivolumab, or pembrolizumab were invited toparticipate in a survey about their experiences during treatment. Quality of life was evaluated usingthe Functional Assessment of Cancer Therapy–General (FACT-G). Common symptomatic adverseevents were evaluated using an item bank generated for ICIs. Internationally, 226 patients (meanage 61, 75% female) participated. Patients reported worse quality of life at the time of assessmentthan U.S. population and cancer normative samples. The most common moderate to severe adverseevents during ICI treatment were fatigue (41%), aching joints (27%), and aching muscles (20%). Dueto toxicity, 25% reported a treatment delay, 11% an emergency room visit, and 9% a hospitalization.This study is among the first to our knowledge to report on PROs of ICIs outside the context of aclinical trial. Results suggest higher rates of adverse events than previously reported in clinical trials.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

PubMed ID

33396286

Language

English

Download

Share

COinS